Unknown

Dataset Information

0

Increasing CRISPR Efficiency and Measuring Its Specificity in HSPCs Using a Clinically Relevant System.


ABSTRACT: Genome editing of human cluster of differentiation 34+ (CD34+) hematopoietic stem and progenitor cells (HSPCs) holds great therapeutic potential. This study aimed to optimize on-target, ex vivo genome editing using the CRISPR-Cas9 system in CD34+ HSPCs and to create a clear workflow for precise identification of off-target effects. Modified synthetic guide RNAs (gRNAs), either 2-part gRNA or single-guide RNA (sgRNA), were delivered to CD34+ HSPCs as part of ribonucleoprotein (RNP) complexes, targeting therapeutically relevant genes. The addition of an Alt-R electroporation enhancer (EE), a short, single-stranded oligodeoxynucleotide (ssODN), significantly increased editing efficiency in CD34+ HSPCs. Notably, similar editing improvement was observed when excess gRNA over Cas9 protein was used, providing a DNA-free alternative suitable for therapeutic applications. Furthermore, we demonstrated that sgRNA may be preferable over 2-part gRNA in a locus-specific manner. Finally, we present a clear experimental framework suitable for the unbiased identification of bona fide off-target sites by Genome-Wide, Unbiased Identification of Double-Strand Breaks (DSBs) Enabled by Sequencing (GUIDE-seq), as well as subsequent editing quantification in CD34+ HSPCs using rhAmpSeq. These findings may facilitate the implementation of genome editing in CD34+ HSPCs for research and therapy and can be adapted for other hematopoietic cells.

SUBMITTER: Shapiro J 

PROVIDER: S-EPMC7251314 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Increasing CRISPR Efficiency and Measuring Its Specificity in HSPCs Using a Clinically Relevant System.

Shapiro Jenny J   Iancu Ortal O   Jacobi Ashley M AM   McNeill Matthew S MS   Turk Rolf R   Rettig Garrett R GR   Amit Ido I   Tovin-Recht Adi A   Yakhini Zohar Z   Behlke Mark A MA   Hendel Ayal A  

Molecular therapy. Methods & clinical development 20200504


Genome editing of human cluster of differentiation 34<sup>+</sup> (CD34<sup>+</sup>) hematopoietic stem and progenitor cells (HSPCs) holds great therapeutic potential. This study aimed to optimize on-target, <i>ex vivo</i> genome editing using the CRISPR-Cas9 system in CD34<sup>+</sup> HSPCs and to create a clear workflow for precise identification of off-target effects. Modified synthetic guide RNAs (gRNAs), either 2-part gRNA or single-guide RNA (sgRNA), were delivered to CD34<sup>+</sup> HSPC  ...[more]

Similar Datasets

| S-EPMC6903732 | biostudies-literature
| S-EPMC4250831 | biostudies-literature
| S-EPMC6587970 | biostudies-literature
| S-EPMC7396914 | biostudies-literature
| S-EPMC4856574 | biostudies-literature
| S-EPMC4338555 | biostudies-literature
| S-EPMC6626619 | biostudies-literature
| S-EPMC6325910 | biostudies-literature
| S-EPMC4371985 | biostudies-literature
| S-EPMC6181213 | biostudies-literature